Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122653582 | 12265358 | 2 | F | 20160525 | 20160716 | 20160413 | 20160719 | EXP | PHHY2016MX048614 | NOVARTIS | 85.72 | YR | F | Y | 0.00000 | 20160719 | CN | COUNTRY NOT SPECIFIED | MX |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122653582 | 12265358 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | PATCH 5 (CM2), QD | 657110 | 22083 | 4.6 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||||
| 122653582 | 12265358 | 2 | C | HALOPERIDOL. | HALOPERIDOL | 1 | Unknown | UNK | 0 | ||||||||||
| 122653582 | 12265358 | 3 | C | CLONAZEPAM. | CLONAZEPAM | 1 | Unknown | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122653582 | 12265358 | 1 | Memory impairment |
| 122653582 | 12265358 | 2 | Product used for unknown indication |
| 122653582 | 12265358 | 3 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122653582 | 12265358 | DE |
| 122653582 | 12265358 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122653582 | 12265358 | Abasia | |
| 122653582 | 12265358 | Death | |
| 122653582 | 12265358 | Embolism | |
| 122653582 | 12265358 | Malaise |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |